Healthcare Services

Neurological Disorder Diagnostics Market Developments Influencing Industry Expansion Through 2030

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Neurological Disorder Diagnostics Market Change Between 2026 And 2030?

The neurological disorder diagnostics market size has shown substantial growth recently. It is anticipated to increase from $12.61 billion in 2025 to $13.54 billion in 2026, registering a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be linked to the rising incidence of neurological conditions, a greater understanding of the importance of early diagnosis, the expansion of sophisticated imaging infrastructure, increased funding for neurological research, and improved access to diagnostic equipment.

The neurological disorder diagnostics market size is projected for substantial expansion in the coming years. It is anticipated to reach $17.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is attributable to several factors, including the increasing implementation of precision neurology approaches, growing investments in digital diagnostics platforms, the widening scope of personalized treatment planning, the expanding utilization of tele-neurology services, and progress in neuroinformatics and analytics. Key trends expected during this period involve the increasing uptake of AI-assisted neuroimaging tools, a rise in the application of biomarker-based diagnostic kits, the broadening integration of genetic and molecular testing, the expansion of remote and digital cognitive assessments, and a heightened emphasis on early disease detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19611&type=smp

What Influential Factors Are Boosting The Neurological Disorder Diagnostics Market Demand?

The rising occurrence of Alzheimer’s disease is anticipated to drive the expansion of the neurological disorder diagnostics market in the future. Alzheimer’s disease is defined as a progressive neurodegenerative condition marked by a slow deterioration of cognitive abilities, such as memory, reasoning, and problem-solving skills. This condition involves a combination of elements, including genetic factors like specific gene mutations and variations, the buildup of amyloid plaques and tau tangles in the brain, persistent inflammation, vascular problems, and lifestyle choices. Diagnostics for neurological disorders assist in managing Alzheimer’s by facilitating early and precise identification via sophisticated imaging methods, biomarker examinations, and cognitive evaluations. For example, reports from September 2024 by the Australian Institute of Health and Welfare, an Australia-based government entity, indicated that in 2023, approximately 411,100 individuals in Australia were living with dementia, comprising about 257,500 women and 153,700 men. Consequently, the growing incidence of Alzheimer’s disease is propelling the expansion of the neurological disorder diagnostics market.

What Are The Major Segment Categories Within The Neurological Disorder Diagnostics Market?

The neurological disorder diagnostics market covered in this report is segmented –

1) By Component: Instruments, Reagents, Kits, Software, Services

2) By Technology: Immunoassay, Polymerase Chain Reaction (PCR) Techniques

3) By Disease Type: Alzheimer’s Disease, Dementia, Parkinson’s Disease, Epilepsy, Traumatic Brain Injury, Other Disease Types

4) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes

Subsegments:

1) By Instruments: Electroencephalography (EEG) Machines, Magnetic Resonance Imaging (MRI) Machines, Computed Tomography (CT) Scanners, Positron Emission Tomography (PET) Scanners, Lumbar Puncture Equipment, Ultrasound Devices, Neurostimulation Devices, Transcranial Magnetic Stimulation (TMS) Devices,

2) By Reagents: Biochemical Reagents, Antibodies, DNA Probes, RNA Probes, Enzyme-linked Immunosorbent Assay (ELISA) Reagents, Polymerase Chain Reaction (PCR) Reagents, Sample Collection Reagents

3) By Kits: Diagnostic Test Kits, Genetic Testing Kits, Biomarker Detection Kits, Immunoassay Kits, Point-of-Care Testing Kits, Screening Kits for Neurological Disorders

4) By Software: Diagnostic Software for Imaging Analysis, Data Management Software, Clinical Decision Support Software, Patient Management Software, Laboratory Information Management Systems (LIMS), Neuroinformatics Software, Telemedicine Software

5) By Services: Diagnostic Testing Services, Consultation Services, Training and Support Services, Maintenance and Repair Services for Equipment, Telehealth Services, Data Analysis Services, Research and Development Services

Which Trends Are Guiding The Development Of The Neurological Disorder Diagnostics Market?

Leading companies in the neurological biomarkers market are developing innovative products, including advanced biomarker blood tests, to achieve a competitive advantage. Biomarker blood tests involve the examination of specific molecules or indicators in the blood to provide data regarding a biological condition, illness, or physiological process. For example, in July 2023, Quanterix Corporation, a US-based entity focused on the development and marketing of ultra-sensitive digital immunoassay platforms, introduced the LucentAD biomarker blood test. The LucentAD test is designed to assist medical practitioners in assessing patients who exhibit cognitive symptoms consistent with early signs of Alzheimer’s disease. This test measures the levels of p-Tau 181, which has been identified as a biomarker for the pathophysiology of Alzheimer’s disease (AD). For adults being tested for AD 1 with cognitive impairment, the results of the LucentAD test are intended for use as a diagnostic tool. The test is not to be used as a standalone screening or diagnostic assay and must be utilized alongside other diagnostic instruments.

Who Are The Firms Contributing To The Neurological Disorder Diagnostics Market Ecosystem?

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation

Access The Complete Neurological Disorder Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-diagnostics-global-market-report

Which Region Commands The Largest Share Of The Neurological Disorder Diagnostics Market?

North America was the largest region in the neurological disorder diagnostics market in 2025. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurological Disorder Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=19611&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Diagnostics Market 2026, By The Business Research Company

Central Nervous System Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Clinical Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795